Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) (REFS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01830959

Recruitment Status : Unknown

Verified December 2015 by Robert P Baughman, University of Cincinnati.
Recruitment status was: Active, not recruiting

First Posted : April 12, 2013

Last Update Posted : December 8, 2015

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

The Cleveland Clinic

University of Pittsburgh

University of Illinois at Chicago

Henry Ford Health System

Albany Medical College

Information provided by (Responsible Party):

Robert P Baughman, University of Cincinnati

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	May 2016
Estimated Study Completion Date :	October 2016

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Baughman RP, Judson MA, Culver DA, Birring SS, Parambil J, Zeigler J, Lower EE. Roflumilast (Daliresp(R)) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis. 2021;38(3):e2021035. doi: 10.36141/svdld.v38i3.11684. Epub 2021 Sep 30.

To Top